Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,279 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 2 Interventional Results available

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

NCT03530696
View directory record Official record
Conditions
HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
Palbociclib, T-DM1
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

NCT00567203
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-3463275, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Glendale, California • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2008 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer

NCT00194727
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Vinorelbine, Capecitabine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01499290
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
CAZ-AVI, Metronidazole, Meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

NCT01396161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 30, 2026, 4:02 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

NCT04018274
View directory record Official record
Conditions
Healthy
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 30, 2026, 4:02 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

NCT06079320
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Sisunatovir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Garden Grove, California • Westminster, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 4:02 PM EDT
Suspended Phase 1 Interventional

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

NCT03065062
View directory record Official record
Conditions
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
Interventions
Palbociclib, Gedatolisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NCT00038103
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Celecoxib + Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 30, 2026, 4:02 PM EDT
Completed No phase listed Observational Results available

Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

NCT03975790
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

NCT01995513
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Abiraterone, Placebo for Enzalutamide, Prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
6
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

NCT00054886
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
SU-011,248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Los Angeles, California • Mission Hills, California • Monterey Park, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

NCT01537497
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

NCT01367834
View directory record Official record
Conditions
Turner Syndrome
Interventions
somatotropin
Drug
Lead sponsor
Rebecca Knickmeyer Santelli, PhD
Other
Eligibility
11 Months to 13 Months · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

NCT01794364
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

NCT01025336
View directory record Official record
Conditions
Healthy
Interventions
Blood draw
Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Chandler, Arizona • Phoenix, Arizona • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine or control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Atorvastatin Three Year Pediatric Study

NCT00827606
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 15 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

NCT01121484
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained-release, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 30, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

NCT00037206
View directory record Official record
Conditions
Aspergillosis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 30, 2026, 4:02 PM EDT